News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • DOJ added Joseph diGenova to the Southern District of Florida team probing ex-CIA director John Brennan.
  • The appointment follows staffing changes and internal frustration over the inquiry's timeline in the Miami U.S. Attorney's Office.
  • Trump Organization and local partners plan a 70-story mixed-use 'Trump Tower Tbilisi' in Georgia's capital.
  • Designers say the project would be Tbilisi's tallest building with residences, retail, and hotel-style amenities.
  • The report could not be independently verified and the Trump Organization declined to comment.
  • MOEX closed flat as large caps diverged, with energy and fertilizer stocks outperforming and banks and miners lagging.
  • Commodities and the ruble showed sharp intraday moves while the Russian Volatility Index held steady.

Latest Articles

Brookfield Business Corporation Completes 2025 Annual Filings

Brookfield Business Corporation Completes 2025 Annual Filings

Brookfield Business Corporation has filed its 2025 annual report with the SEC and Canadian securities authorities, including audited financial statements. The company finalized a corporate simplification by exchanging various partnership units for newly issued Class A shares, which will begin trading on the NYSE and TSX under the ticker BBUC starti…

Ellomay Capital Reports Publication of Financial Statements of Dorad Energy Ltd. as of and for the Year Ended December 31, 2025

Ellomay Capital Reports Publication of Financial Statements of Dorad Energy Ltd. as of and for the Year Ended December 31, 2025

Ellomay Capital Ltd. has published the financial statements of Dorad Energy Ltd. for the year ended December 31, 2025. Ellomay holds an indirect 16.9% stake in Dorad through Ellomay Luzon Energy. Dorad reported revenues of approximately NIS 2.65 billion and an operating profit of NIS 385 million for 2025. The results were impacted by seasonal elect…

Data Storage Corporation Postpones 2025 Fiscal Year Conference Call

Data Storage Corporation Postpones 2025 Fiscal Year Conference Call

Data Storage Corporation announced the postponement of its fiscal year 2025 investor conference call to allow more time to complete its year-end audit. The audit complexity stems from significant transactions including the sale of its CloudFirst subsidiary, warrant settlements, and a tender offer. A new date for the earnings call will be announced …

HeartCore Reports Full Year 2025 Results

HeartCore Reports Full Year 2025 Results

HeartCore Enterprises, Inc., a Tokyo-based IPO consulting services company listed on Nasdaq (HTCR), announced its full year 2025 results. The company reported revenues of $9.0 million, gross profit of $3.2 million, and net income of $5.5 million compared to a net loss last year. The positive net income was primarily due to gains from the divestitur…

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics announced progress in developing their lead candidate, Zervimesine (CT1812), for neurodegenerative diseases. Positive Phase 2 SHIMMER trial results support advancing the drug to late-stage trials for dementia with Lewy bodies (DLB) psychosis. The ongoing fully funded Phase 2 START trial in mild cognitive impairment and early …

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial evaluating TP-05 (lotilaner), an investigational oral systemic therapy aimed at preventing Lyme disease by killing infected ticks before transmission. The randomized, placebo-controlled trial will enroll approximately 700 adults at risk across endemic U.S. regions,…

BIO-key Reports 2025 Results and Substantially Improved Cash Position, Supporting Expected Strong Growth in 2026; Investor Call Today at 10am ET

BIO-key Reports 2025 Results and Substantially Improved Cash Position, Supporting Expected Strong Growth in 2026; Investor Call Today at 10am ET

BIO-key International announced its 2025 financial results showing $6.1M revenue with a 12% decline from 2024 due to strategic shifts in the EMEA region. The company improved its cash position to $2.7M and expects solid revenue growth and improved profitability in 2026, driven by increased demand in foreign military, defense, financial sectors, and…

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Ltd. has begun submitting its New Drug Application for D-PLEX100 to the FDA under a rolling review process, targeting approval by Q2 2026. The lead product, designed to prevent surgical site infections after colorectal surgery, demonstrated significant efficacy in Phase 3 trials and has received FDA Breakthrough Therapy Designation. The com…

GoHealth Prioritizes Consumer Fit, Renewal Economics and Cash Discipline While Continuing Leadership in Special Needs Plans; Reports Full Year 2025 Results

GoHealth Prioritizes Consumer Fit, Renewal Economics and Cash Discipline While Continuing Leadership in Special Needs Plans; Reports Full Year 2025 Results

GoHealth, Inc. announced its full year 2025 financial results, emphasizing a strategic pullback in Medicare Advantage enrollments due to market conditions. The company prioritized consumer fit, renewal economics, cash discipline, and continued leadership in specialized needs plans (SNPs). GoHealth invested in AI and technology to improve efficiency…

BlockchAIn Reports Full Year 2025 Financial Results and Highlights Commercial Momentum Following Public Listing

BlockchAIn Reports Full Year 2025 Financial Results and Highlights Commercial Momentum Following Public Listing

BlockchAIn Digital Infrastructure, Inc. (NYSE American: AIB) completed its business combination and began public trading in March 2026. The company operates a 40 MW data center and is advancing its growth plans with over $500 million in potential contract value from letters of intent. BlockchAIn focuses on AI and HPC digital infrastructure developm…

Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone

Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone

Nuwellis, Inc. announced that its pediatric category has become its largest and fastest-growing revenue segment, comprising approximately 50% of total U.S. revenue in 2025. The Aquadex therapy platform's adoption has expanded to 47 pediatric centers, including six of the top 10 children's hospitals, reflecting strong clinical acceptance and strateg…

Skeena Gold & Silver Announces Proposed USD$750 Million Senior Secured Notes Offering to Refinance Former Project Financing and to Fund Partial Buyback of Existing Gold Stream

Skeena Gold & Silver Announces Proposed USD$750 Million Senior Secured Notes Offering to Refinance Former Project Financing and to Fund Partial Buyback of Existing Gold Stream

Skeena Resources Limited announces a proposed $750 million offering of Senior Secured Notes due 2031 to refinance former project financing and fund a partial buyback of its existing $200 million gold stream. The transaction aims to improve operating margins, increase exposure to gold prices, and enhance project economics for the Eskay Creek Gold-Si…

Edible Garden Reports 2025 Results — Accelerates Planned Expansion into Higher-Margin Ready-to-Drink (RTD) and Shelf-Stable CPG Platform

Edible Garden Reports 2025 Results — Accelerates Planned Expansion into Higher-Margin Ready-to-Drink (RTD) and Shelf-Stable CPG Platform

Edible Garden AG Incorporated reported its 2025 financial results, highlighting strategic expansion beyond controlled environment agriculture into higher-margin ready-to-drink (RTD) and shelf-stable consumer packaged goods. The company increased its retail footprint to nearly 6,000 locations, including major partners like Kroger and Amazon, and is …

Kartoon Studios Provides Business Update

Kartoon Studios Provides Business Update

Kartoon Studios announced a 21% increase in total revenue to $39.4 million for 2025, driven largely by a 50% growth in animation production services. The company's operating loss improved by 24%, reflecting cost discipline and a shift toward higher-margin franchise monetization. Kartoon Studios is scaling its distribution platforms with record subs…

Foremost Clean Energy Closes Bought Deal Private Placement for Aggregate Gross Proceeds of C$5.7 Million

Foremost Clean Energy Closes Bought Deal Private Placement for Aggregate Gross Proceeds of C$5.7 Million

Foremost Clean Energy Ltd. completed a bought deal private placement raising aggregate gross proceeds of C$5.7 million by issuing flow-through units to support exploration of its uranium and lithium properties in Canada. The capital will be used to incur qualifying Canadian exploration expenses on the company's mineral properties in Saskatchewan an…

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

Cadrenal Therapeutics reported strong fourth quarter and full-year 2025 results, highlighted by positive Phase 2 clinical data for its lead drug CAD-1005 treating heparin-induced thrombocytopenia (HIT). The company completed an End-of-Phase 2 meeting with the FDA, clarifying the regulatory strategy for its Phase 3 pivotal trial. CAD-1005 showed a s…

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

Pelthos Therapeutics announced the dosing of the first patient in a Phase 1b/2a clinical trial evaluating CT2000, an investigational NaV1.7 inhibitor eye drop formulation, as a treatment for acute and chronic ocular pain associated with dry eye disease. The trial will assess safety and efficacy with results expected by the end of 2026. Positive pre…

Dycom Industries, Inc. Appoints Company Veteran Bo Gresham as its First Chief Revenue Officer to Lead Next Phase of Growth

Dycom Industries, Inc. Appoints Company Veteran Bo Gresham as its First Chief Revenue Officer to Lead Next Phase of Growth

Dycom Industries appoints industry veteran Bo Gresham as its first Chief Revenue Officer to lead revenue growth and strategic market expansion amid a multi-year boom in digital infrastructure and fiber deployments. With nearly 30 years of experience, Gresham's promotion reflects Dycom's commitment to internal talent development and positions the co…

Micron Announces the Pricing of the Cash Tender Offers for Any and All of Certain Outstanding Senior Notes

Micron Announces the Pricing of the Cash Tender Offers for Any and All of Certain Outstanding Senior Notes

Micron Technology announced the pricing and terms for cash tender offers to repurchase various series of its outstanding senior notes, totaling several billion dollars. The offers include specific reference yields and notes considerations, with an expiration date of March 31, 2026, and expected settlement on April 3, 2026. The company emphasizes th…